vs
Side-by-side financial comparison of Laird Superfood, Inc. (LSF) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $13.3M, roughly 1.7× Laird Superfood, Inc.). Laird Superfood, Inc. runs the higher net margin — -13.2% vs -416.2%, a 403.0% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 15.0%). Over the past eight quarters, Laird Superfood, Inc.'s revenue compounded faster (16.1% CAGR vs -10.8%).
Laird Superfood, Inc. develops, manufactures and sells a portfolio of plant-based functional superfood products, including premium coffee creamers, hydration blends, nutritional supplements, and plant-powered snacks. It serves health-conscious consumers through direct-to-consumer e-commerce platforms and offline retail partners, mainly operating in the North American market with a focus on sustainably sourced clean ingredients.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
LSF vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.3M | $23.0M |
| Net Profit | $-1.8M | $-95.8M |
| Gross Margin | 34.1% | — |
| Operating Margin | -13.5% | -428.9% |
| Net Margin | -13.2% | -416.2% |
| Revenue YoY | 15.0% | 78.8% |
| Net Profit YoY | -341.4% | 25.7% |
| EPS (diluted) | — | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.3M | $23.0M | ||
| Q3 25 | $12.9M | $13.8M | ||
| Q2 25 | $12.0M | $14.2M | ||
| Q1 25 | $11.7M | $16.6M | ||
| Q4 24 | $11.6M | $12.9M | ||
| Q3 24 | $11.8M | $9.1M | ||
| Q2 24 | $10.0M | $7.0M | ||
| Q1 24 | $9.9M | $28.9M |
| Q4 25 | $-1.8M | $-95.8M | ||
| Q3 25 | $-975.1K | $-101.3M | ||
| Q2 25 | $-362.2K | $-101.3M | ||
| Q1 25 | $-156.2K | $-114.3M | ||
| Q4 24 | $-398.4K | $-128.9M | ||
| Q3 24 | $-166.1K | $-135.7M | ||
| Q2 24 | $-239.1K | $-147.0M | ||
| Q1 24 | $-1.0M | $-107.4M |
| Q4 25 | 34.1% | — | ||
| Q3 25 | 36.5% | — | ||
| Q2 25 | 39.9% | — | ||
| Q1 25 | 41.9% | — | ||
| Q4 24 | 38.6% | — | ||
| Q3 24 | 43.0% | — | ||
| Q2 24 | 41.8% | — | ||
| Q1 24 | 40.0% | — |
| Q4 25 | -13.5% | -428.9% | ||
| Q3 25 | -7.7% | -808.9% | ||
| Q2 25 | -3.3% | -772.2% | ||
| Q1 25 | -1.9% | -726.6% | ||
| Q4 24 | -4.1% | -1059.9% | ||
| Q3 24 | -2.3% | -1589.0% | ||
| Q2 24 | -3.4% | -1998.6% | ||
| Q1 24 | -11.0% | -394.0% |
| Q4 25 | -13.2% | -416.2% | ||
| Q3 25 | -7.6% | -735.2% | ||
| Q2 25 | -3.0% | -710.8% | ||
| Q1 25 | -1.3% | -687.6% | ||
| Q4 24 | -3.4% | -1001.2% | ||
| Q3 24 | -1.4% | -1489.5% | ||
| Q2 24 | -2.4% | -2112.6% | ||
| Q1 24 | -10.3% | -371.3% |
| Q4 25 | — | $-0.81 | ||
| Q3 25 | — | $-0.92 | ||
| Q2 25 | — | $-0.98 | ||
| Q1 25 | — | $-1.10 | ||
| Q4 24 | — | $-1.27 | ||
| Q3 24 | — | $-1.34 | ||
| Q2 24 | — | $-1.52 | ||
| Q1 24 | — | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.1M | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $11.5M | $671.4M |
| Total Assets | $19.2M | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.1M | $449.9M | ||
| Q3 25 | $5.1M | $511.0M | ||
| Q2 25 | $3.9M | $459.7M | ||
| Q1 25 | $7.0M | $503.7M | ||
| Q4 24 | $8.3M | $601.5M | ||
| Q3 24 | $7.9M | $658.1M | ||
| Q2 24 | $7.6M | $691.1M | ||
| Q1 24 | $7.1M | $791.3M |
| Q4 25 | $11.5M | $671.4M | ||
| Q3 25 | $12.8M | $748.4M | ||
| Q2 25 | $13.4M | $715.3M | ||
| Q1 25 | $13.3M | $779.9M | ||
| Q4 24 | $13.2M | $872.0M | ||
| Q3 24 | $13.1M | $962.6M | ||
| Q2 24 | $12.6M | $971.1M | ||
| Q1 24 | $12.7M | $1.0B |
| Q4 25 | $19.2M | $842.1M | ||
| Q3 25 | $18.9M | $925.3M | ||
| Q2 25 | $20.4M | $898.9M | ||
| Q1 25 | $21.5M | $986.2M | ||
| Q4 24 | $19.3M | $1.2B | ||
| Q3 24 | $18.8M | $1.2B | ||
| Q2 24 | $18.0M | $1.2B | ||
| Q1 24 | $17.6M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $68.4K | $-69.3M |
| Free Cash FlowOCF − Capex | — | $-69.4M |
| FCF MarginFCF / Revenue | — | -301.6% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $68.4K | $-69.3M | ||
| Q3 25 | $1.2M | $-76.9M | ||
| Q2 25 | $-2.8M | $-99.6M | ||
| Q1 25 | $-1.3M | $-148.9M | ||
| Q4 24 | $339.2K | $-85.2M | ||
| Q3 24 | $305.8K | $-84.8M | ||
| Q2 24 | $642.7K | $-58.2M | ||
| Q1 24 | $-422.3K | $-120.7M |
| Q4 25 | — | $-69.4M | ||
| Q3 25 | — | $-76.9M | ||
| Q2 25 | — | $-99.9M | ||
| Q1 25 | — | $-149.7M | ||
| Q4 24 | — | $-86.2M | ||
| Q3 24 | — | $-86.1M | ||
| Q2 24 | — | $-59.2M | ||
| Q1 24 | — | $-123.2M |
| Q4 25 | — | -301.6% | ||
| Q3 25 | — | -558.2% | ||
| Q2 25 | — | -701.0% | ||
| Q1 25 | — | -900.1% | ||
| Q4 24 | — | -669.4% | ||
| Q3 24 | — | -945.2% | ||
| Q2 24 | — | -850.9% | ||
| Q1 24 | — | -425.7% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | — | 7.6% | ||
| Q3 24 | — | 14.0% | ||
| Q2 24 | — | 14.5% | ||
| Q1 24 | — | 8.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
